Tirzepatide improved markers of beta-cell function and insulin sensitivity significantly more than semaglutide in nearly 1,900 people with type 2 diabetes.
120% vs 84%Maximum improvement in beta-cell function with tirzepatide 15 mg versus semaglutide 1 mg
What the researchers found
In this post hoc analysis of the SURPASS-2 trial, tirzepatide at all three doses (5, 10, and 15 mg) outperformed semaglutide 1 mg in improving both pancreatic beta-cell function and insulin sensitivity in people with type 2 diabetes over 40 weeks.
Tirzepatide improved HOMA2-B (beta-cell function) by 96.9–120.4% compared to 84.0% with semaglutide (p<0.05). Insulin resistance (HOMA2-IR) decreased by 15.5–24.0% with tirzepatide versus only 5.1% with semaglutide (p<0.05). Tirzepatide 10 and 15 mg also significantly reduced fasting C-peptide (5.2–6.0%) and fasting glucagon (53.0–55.3%) compared to semaglutide. These advantages in HbA1c and weight loss held across all baseline quartiles of beta-cell function and insulin resistance.
Why it matters
This head-to-head comparison with semaglutide — the leading GLP-1 drug — demonstrates that tirzepatide's dual GIP/GLP-1 mechanism produces superior improvements in the fundamental metabolic defects of type 2 diabetes: failing beta cells and insulin resistance. This goes beyond symptom management to address root causes.
The numbers in context
n=1,879 · 40 weeks · HOMA2-B improvement: 96.9–120.4% (tirzepatide) vs 84.0% (semaglutide) · HOMA2-IR reduction: 15.5–24.0% vs 5.1% · p<0.05
How the study worked
Post hoc analysis of the SURPASS-2 phase 3 randomized controlled trial. 1,879 participants with type 2 diabetes across 128 sites in 8 countries were assigned to weekly subcutaneous tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg for 40 weeks. Biomarkers of beta-cell function (HOMA2-B) and insulin resistance (HOMA2-IR), along with fasting glucagon, C-peptide, and insulin were measured.
Who was studied
Adults with type 2 diabetes across 128 sites in 8 countries
What this study cannot tell us
This is a post hoc analysis, not a prespecified endpoint, which means the findings are hypothesis-generating rather than confirmatory. The semaglutide comparator was limited to 1 mg (the maximum approved dose at trial initiation), not the higher 2 mg dose now available.
How to read the evidence
This is a post hoc analysis of a large phase 3 RCT (SURPASS-2) with 1,879 participants. While post hoc analyses are not as definitive as prespecified endpoints, the large sample size, rigorous trial design, and consistent results across dose groups support a high evidence grade.
When this study was published
Published in 2024, this analysis reflects the most current clinical evidence comparing tirzepatide and semaglutide on metabolic biomarkers.
The bigger picture
The competition between tirzepatide and semaglutide is reshaping diabetes and obesity treatment. While both drugs reduce blood sugar and weight, this study suggests tirzepatide may have a fundamental advantage in addressing the core metabolic defects of type 2 diabetes — potentially slowing disease progression rather than just managing symptoms.
Questions still open
- Would higher-dose semaglutide (2 mg) narrow the gap with tirzepatide on these metabolic markers?
- Do these improvements in beta-cell function translate to longer-term diabetes remission or reduced need for insulin therapy?
- Is tirzepatide's advantage driven primarily by its GIP activity, its GLP-1 activity, or the combination?
Common questions
How does tirzepatide differ from semaglutide mechanistically?
What does improved beta-cell function mean for diabetes patients?
Read the original research
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
The Journal of clinical endocrinology and metabolism, 109(7), 1745-1753
Citation
Frias, Juan P; De Block, Christophe; Brown, Katelyn; Wang, Hui; Thomas, Melissa K; Zeytinoglu, Meltem; Maldonado, Juan M. (2024). Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).. The Journal of clinical endocrinology and metabolism, 109(7), 1745-1753. https://doi.org/10.1210/clinem/dgae038